When considering CD133+ cells for clinical application, allogenic cells might be the preferred choice for the treatment of DMD, since CD133+ cells derived from DMD muscle showed lower overall performance after i.m. injection into an immunodeficient, non-dystrophic, mouse muscle [60]. The gene discussed is PROM1; the disease is Duchenne muscular dystrophy.